SCHEMBL10068076

SCHEMBL10068076

CC(=O)[C@H](C)CCCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
LMNA P02545 2/20 0.46
SLC22A6 Q4U2R8 2/20 0.46
FFAR4 Q5NUL3 1/20 0.45
FFAR1 O14842 1/20 0.45
GABRP O00591 2/20 0.44
GABRD O14764 2/20 0.44
GABRA1 P14867 2/20 0.44
GABRB1 P18505 2/20 0.44
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRA5 P31644 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA2 P47869 2/20 0.44
GABRB2 P47870 2/20 0.44
GABRA4 P48169 2/20 0.44
GABRE P78334 2/20 0.44
GABRA6 Q16445 2/20 0.44
GABRG1 Q8N1C3 2/20 0.44
GABRG3 Q99928 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348647 1.00 CYP1A2 (0.50) CYP1A2LMNASLC22A6FFAR4FFAR1
SCHEMBL999059 0.93 FFAR4 (0.53) CYP1A2LMNASLC22A6FFAR4FFAR1
SCHEMBL559468 0.91 FFAR4 (0.57) LMNASLC22A6FFAR4FFAR1TSHR
SCHEMBL14093813 0.91 FFAR4 (0.57) LMNASLC22A6FFAR4FFAR1TSHR
SCHEMBL304217 0.91 FFAR4 (0.57) LMNASLC22A6FFAR4FFAR1TSHR
SCHEMBL28041784 0.86 FFAR4 (0.52) LMNASLC22A6FFAR4FFAR1TSHR
SCHEMBL12658700 0.85 CYP1A2 (0.68) CYP1A2LMNAGABRPGABRDGABRA1
SCHEMBL14197461 0.85 CYP1A2 (0.68) CYP1A2LMNAGABRPGABRDGABRA1
SCHEMBL2344610 0.85 CYP1A2 (0.68) CYP1A2LMNAGABRPGABRDGABRA1
SCHEMBL279916 0.83 CYP1A2 (0.73) CYP1A2LMNASLC22A6FFAR4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9110069-B2 Luminescent compounds SETA BIOMEDICALS, LLC (US) 2015-08-18 US disclosed
US-20140086844-A1 LUMINESCENT COMPOUNDS SETA BIOMEDICALS, LLC (US) 2014-03-27 US disclosed
US-8642014-B2 Luminescent compounds SETA BIOMEDICALS, LLC (US) 2014-02-04 US disclosed
US-8552027-B2 Luminescent compounds SETA BIOMEDICALS, LLC (US) 2013-10-08 US disclosed
US-20120035346-A1 LUMINESCENT COMPOUNDS SETA BIOMEDICALS, LLC 2012-02-09 US disclosed
US-7411068-B2 Luminescent compounds SETA BIOMEDICALS, LLC 2008-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140086844-A1 LUMINESCENT COMPOUNDS PHOSPHO1, PGLS, PFAS CYP1A2 3724/4885LMNA 986/4885SLC22A6 3671/4885
US-20120035346-A1 LUMINESCENT COMPOUNDS PHOSPHO1, PGLS, PFAS CYP1A2 3737/4885LMNA 1037/4885SLC22A6 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.